ReviewCureus2026
Unicentric Castleman Disease of the Mesentery: A Systematic Review.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Castleman disease (CD) is a rare lymphoproliferative disorder categorized into unicentric and multicentric forms. The unicentric form usually manifests as a localized lymph node enlargement. Mesenteric involvement is rare and can mimic other intra-abdominal neoplasms such as gastrointestinal stromal tumors, lymphoma, or metastatic disease, making preoperative diagnosis difficult. The study aimed to systematically analyze published cases of mesenteric unicentric CD (UCD) and evaluate demographic trends, anatomical distribution, histopathological variants, tumor characteristics, treatment strategies, and clinical outcomes. A systematic review of individual case reports published between 1996 and 2026 was performed following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) framework. The literature search was conducted using PubMed and Scopus as the primary databases. Reports describing mesenteric UCD were screened, and relevant details, including age, sex, lesion size, location, histopathology, and management, were extracted. Data were summarized using descriptive statistics and synthesized narratively. The mean age at diagnosis was 35.3 ± 17.9 years, and the mean lesion size was 5.51 ± 2.25 cm. The mesentery (unspecified) was the most frequently reported site (75.68%), followed by the small bowel mesentery (18.92%) and large bowel mesentery (5.41%). The prevalence of mesenteric UCD with a hyaline vascular variant was 64.86%, followed by plasma cell (21.62%) and mixed types (12.16%). In 1.35% of cases, histology was not specified. Complete surgical excision represented the primary therapeutic approach (60.81%) and was associated with favorable outcomes in most patients. For mesenteric UCD, surgical excision remains the cornerstone of treatment, offering an excellent prognosis. Early recognition and accurate histopathological diagnosis are essential to avoid misclassification and guide optimal management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.